Journal of Psychedelic Studies
July 17, 2024
Liam Engel, Sascha Thal, Stephen Bright et al.
4 citations
Analysis of 660 posts from online psychedelic forums (The Shroomery and DMT Nexus) about trip sitting revealed that psychedelics discussed include 5-MeO-DMT, ayahuasca, changa, LSA, LSD, and psilocybin. For well-researched substances like LSD and psilocybin, the common dosages determined by a Delphi-style expert panel aligned closely with those used in clinical studies. Many posts indicated that psychedelic care was seen as unnecessary or optional, especially for LSD and LSA, while 5-MeO-DMT was strongly associated with a perceived need for care. Greater psychedelic purity and dosage intensity correlated with a perceived need for care. Oral administration, the most common route, showed lower dosage intensity.
Contemporary Drug Problems
February 10, 2025
Liam B. Engel, Mitchell Low
1 citation
Conflicts around the mescaline cacti San Pedro and Peyote arise from tensions between Indigenous cultural practices, psychopharmacotherapy research, psychedelic markets, and ecology. Through autoethnography, the authors reflect on their lived experiences with growing, researching, and working with these plants. They find that powers of medicine and prohibition dominate among diverse stakeholders, but these powers are also met with resistance.
BMC Medicine
July 6, 2026
Hannah Adler, Rebecca Filipic, Dr Maria Gonzalez et al.
Healthcare professionals show interest in psychedelic-assisted therapy with psilocybin for existential distress in people with cancer, but face knowledge gaps, barriers, and a desire for more research. Interviews with 11 professionals from Australian cancer centers revealed four themes: varied knowledge about the therapy, conceptualizing its practical use, navigating complex provision and engagement, and envisioning future applications. Professionals preferred delivery by multidisciplinary teams that are culturally sensitive and ethically rigorous. Some saw it as a last resort, while others viewed it as another needed tool. The findings offer preliminary insights into implementation pathways for this therapy in oncology settings.
Scientific reports
November 20, 2025
Daniel Perkins, Andreas Halman, Anna Urokohara et al.
Acute subjective experiences induced by psychedelics, particularly mystical experiences, are linked to therapeutic benefits such as reduced depression, anxiety, and addiction. This study assessed a purified encapsulated DMT-harmala alkaloid product in 17 dosing sessions with 9 healthy volunteers. Strong positive correlations were found between total dose and scores on mystical experience questionnaires (MEQ-30 and SIME). The formulation reliably produced intense subjective experiences, exceeding those reported in most naturalistic ayahuasca studies, and these experiences were robustly associated with beneficial persisting psychological effects. The findings suggest this formulation warrants further clinical trials to evaluate its therapeutic potential and safety.